Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
12 hedge funds and large institutions have $722K invested in Titan Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
61% more call options, than puts
Call options by funds: $58K | Put options by funds: $36K
0.1% less ownership
Funds ownership: 0.29% → 0.2% (-0.1%)
25% less funds holding
Funds holding: 16 → 12 (-4)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
52% less capital invested
Capital invested by funds: $1.51M → $722K (-$789K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$28.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.21K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.15K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$44 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$151K |
| 2 |
Morgan Stanley
New York
|
-$150K |
| 3 |
VF
Virtu Financial
New York
|
-$87K |
| 4 |
Bank of New York Mellon
New York
|
-$40K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$31.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $386K | +$5.21K | +119 | +1% |
|
|
2
Morgan Stanley
New York
| $169K | -$150K | -3,416 | -43% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $99K | – | – | – |
|
|
4
Group One Trading
Chicago,
Illinois
| $28K | -$31.8K | -726 | -49% |
|
|
5
Renaissance Technologies
New York
| $24K | +$28.5K | +650 | New |
|
6
UBS Group
Zurich,
Switzerland
| $13K | -$2.58K | -59 | -14% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $2K | +$2.15K | +49 | +613% |
|
|
TC
8
Trust Company
Manhattan,
Kansas
| $1K | – | – | – |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| $43 | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$151K | -3,445 | Closed |
|
|
VF
11
Virtu Financial
New York
| – | -$87K | -1,665 | Closed |
|
|
12
Bank of New York Mellon
New York
| – | -$40K | -770 | Closed |
|
|
ASN
13
Advisory Services Network
Atlanta,
Georgia
| – | -$23K | -450 | Closed |
|
14
Bank of America
Charlotte,
North Carolina
| – | -$175 | -4 | -29% |
|
15
JP Morgan Chase
New York
| – | -$44 | -1 | Closed |
|
|
16
Wells Fargo
San Francisco,
California
| – | +$44 | +1 | +50% |
|
TTNP Hedge Fund Activity: Q3 2021 in Review
12 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2021, worth a combined $722K — down 52% from $1.51M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TTNP and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $28.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $151K sold.
- 12 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2021, down from 16 in Q2 2021.
- Funds reported $722K of Titan Pharmaceuticals stock for Q3 2021, down 52% quarter-over-quarter.
- 1 fund opened new Titan Pharmaceuticals positions in Q3 2021 and 5 closed out, a net change of -4 holders.
- The largest Titan Pharmaceuticals buyer in Q3 2021 was Renaissance Technologies, an estimated $28.5K added.
- The largest Titan Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $151K sold.
Based on aggregated 13F filings for Q3 2021.